LMU Researchers Develop AI-Powered Platform to Accelerate RNA Drug Carrier Design
核心洞察
Researchers at LMU Munich have created Bits2Bonds, the first integrated platform combining molecular dynamics simulations and machine learning to identify new polymeric materials for therapeutic RNA delivery.
The computational tool enables rapid virtual screening of thousands of potential carrier molecules before experimental validation, dramatically accelerating the discovery of effective and safe RNA nanocarriers.
The team validated their computational predictions by synthesizing and testing polymer candidates for siRNA delivery, confirming strong correlation between simulated performance and biological efficacy.
A research team led by Professor Olivia Merkel at Ludwig-Maximilians-Universität München (LMU) has developed the first integrated computational platform that combines molecular dynamics simulations and machine learning to identify new polymeric materials for therapeutic RNA delivery. The breakthrough, published in the Journal of the American Chemical Society, introduces a computational tool called Bits2Bonds that enables de novo design and optimization of polymer-based RNA carriers.
The research was conducted within Merkel's ERC Consolidator Grant "RatInhalRNA," which focuses on developing innovative RNA delivery systems for pulmonary administration. Merkel serves as Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic Acid Therapeutics Munich (搜索) (CNATM).
Bridging Computational and Experimental Approaches
Traditional experimental screening of polymer libraries is time-consuming and costly, while purely computational approaches have fallen short due to limited data availability and high computational demands. The Bits2Bonds platform addresses this challenge by integrating coarse-grained molecular dynamics simulations that mimic key biological challenges, such as siRNA binding and membrane interaction, with machine learning-driven molecular design.
The approach allows rapid virtual screening of thousands of potential carrier molecules before experimental validation, dramatically accelerating the discovery of effective and safe RNA nanocarriers.
"Our work demonstrates for the first time that combining physics-based simulation with data-driven optimization can efficiently guide the discovery of entirely new materials for RNA therapeutics," says Olivia Merkel. "This method paves the way for a more rational, high-throughput design of polymeric delivery systems, moving us closer to personalized RNA medicines."
Experimental Validation Confirms Computational Predictions
The research team validated their computational predictions by synthesizing and experimentally testing several polymer candidates for siRNA delivery. The results confirmed a strong correlation between simulated performance and biological efficacy, demonstrating the platform's reliability for predicting real-world therapeutic potential.
Broad Applications for RNA Therapeutics
The resulting pipeline is highly modular and can be adapted to other types of polymers or nucleic acid modalities, including mRNA (搜索) and CRISPR (搜索)-based therapies. This versatility positions the platform as a valuable tool for advancing the broader field of RNA therapeutics, potentially accelerating the development of personalized RNA medicines across multiple therapeutic areas.